UCB S.A.
UCBJY
Other OTC139.15
USD
+4.09
- -
ISIN
US9034801012
CUSIP
903480101
Return %
Stock
S&P500
1Y
37.20
18.99
3Y
209.84
64.75
5Y
163.34
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jean-Christophe Tellier
- Full Time Employees
- 10,117
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Allée de la Recherche, 60 Brussels BU Belgium 1070
- IPO Date
- Aug 3, 2012
- Website
- ucb.com
- Similar Companies
- Business
- UCB SA (UCB.BR; UCBJY) is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines and solutions for severe diseases in neurology and immunology, targeting patients with central nervous system disorders and autoimmune conditions worldwide. Founded in 1928 by Emmanuel Janssen and headquartered in Brussels, Belgium, the company employs over 9,000 people across nearly 40 countries, including major operations in the U.S., Europe, Japan, and China; it offers key products such as BIMZELX (bimekizumab) for psoriasis, hidradenitis suppurativa, and other inflammatory conditions; RYSTIGGO (rozanolixizumab-noli) and ZILBRYSQ (zilucoplan) for generalized myasthenia gravis; FINTEPLA (fenfluramine) for seizures in rare epilepsies; EVENITY (romosozumab) for osteoporosis; BRIVIACT (brivaracetam), KEPPRA (levetiracetam), and VIMPAT (lacosamide) for epilepsy; CIMZIA (certolizumab pegol) for rheumatoid arthritis, psoriatic arthritis, and Crohn's disease; NEUPRO (rotigotine) for Parkinson's disease and restless legs syndrome; and established brands including legacy antihistamines and others undergoing portfolio simplification. UCB generates revenue from these immunology and neurology portfolios, with 2024 sales reaching €6.1 billion and 2025 guidance upgraded to exceed €7.6 billion (24% growth) driven by strong demand for its five growth drivers; recent developments include the November 2024 sale of its mature neurology and allergy business in China to CBC Group and Mubadala for $680 million, forming NeuroGen Pharma; a November 2024 licensing agreement with Bioray for BIMZELX commercialization in China; a June 2025 announcement of a $5 billion U.S. biologics manufacturing facility investment expected to create 300 permanent high-skilled jobs and over 500 construction roles while enhancing supply chain resilience; ongoing global launches and expansions for RYSTIGGO (U.S. 2023, Japan/Europe 2023-2024), ZILBRYSQ, and FINTEPLA; and sustained R&D investment representing about a quarter of revenue into pipeline advancements across neurology, immunology, and rare diseases.
UCB SA (UCBJY) Analyst/Investor Day Transcript
UCB (UCBJY) Upgraded to Strong Buy: Here's What You Should Know
Belgium's UCB in autoimmune drug deal with Antengene
UCB SA (UCBJY) Q4 2025 Earnings Call Transcript
UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Minerva Neurosciences (NASDAQ:NERV) & UCB (OTCMKTS:UCBJY) Head to Head Analysis
UCB (OTCMKTS:UCBJY) Share Price Crosses Above 50 Day Moving Average – What’s Next?
Recent Price Trend in UCB (UCBJY) is Your Friend, Here's Why
UCB (UCBJY) Is a Great Choice for 'Trend' Investors, Here's Why
All You Need to Know About UCB (UCBJY) Rating Upgrade to Strong Buy